Despite diverse levels of evidence supporting the use of biomarkers at various time points in the management pathway for localised prostate cancer, high-level evidence from prospective head-to-head trials for recommending their routine use to inform treatment decisions is still lacking.
Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.